Info

Dominic Romito watches from a standing-room only crowd as hearings proceeded over conflicting interpretations of findings from Sarepta's clinical trial of an experimental drug to treat Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare disease that strikes one in 3500 boys who typically don't survive into their 30's. Sarepta's drug is meant to treat a specific gene mutation. John Boal Photography

Add to Cart Add to Lightbox Download
Filename
JWB 042516 26Sarepta-013-final.JPG
Copyright
John Boal
Image Size
3000x2000 / 695.4KB
Contained in galleries
Dominic Romito watches from a standing-room only crowd as hearings proceeded over conflicting interpretations of findings from Sarepta's clinical trial of an experimental drug to treat Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare disease that strikes one in 3500 boys who typically don't survive into their 30's. Sarepta's drug is meant to treat a specific gene mutation. John Boal Photography